Open Payments

Uh Cleveland Medical Center

Type
Teaching hospital
Where
Cleveland, OH
Medicare CCN
360137
Received
$10,612,982 in 1,682 records, 2023 ($1,229,738 general, $9,383,243 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2023General payment138$1,229,738
2023Research payment1,544$9,383,243

By company

CompanyRecordsAmountYears
SEAGEN INC.197$1,430,6392023
ABBVIE INC.259$942,2352023
Merck Sharp & Dohme LLC29$791,3442023
Cochlear Americas92$784,0102023
Gilead Sciences, Inc.2$488,5662023
Boston Scientific Corporation49$443,3162023
Medtronic, Inc.68$319,8102023
VERTEX PHARMACEUTICALS INCORPORATED8$308,9162023
AstraZeneca UK Limited5$275,6962023
STERIS CORPORATION13$268,5002023
Siemens Medical Solutions USA, Inc.18$254,8122023
Abbott Laboratories62$228,5982023
ARGENX US, INC.70$211,9272023
Becton, Dickinson and Company3$208,8232023
Exelixis Inc.18$192,7572023
Regeneron Pharmaceuticals, Inc.56$181,0282023
Bolton Medical Inc18$169,2922023
Boehringer Ingelheim Pharmaceuticals, Inc.5$165,0832023
AstraZeneca Pharmaceuticals LP8$145,6032023
Eli Lilly and Company20$138,7222023
Ultragenyx Pharmaceutical Inc.14$133,0182023
Janssen Research & Development, LLC11$126,3302023
Genmab U.S., Inc.10$122,3732023
American Regent5$102,9932023
Hoffmann-La Roche Limited5$97,5062023
Stryker Corporation17$95,9282023
Medical Device Business Services, Inc.5$94,8952023
Roche Products Limited12$75,2522023
Takeda Pharmaceuticals U.S.A., Inc.51$73,9672023
Johnson & Johnson Surgical Vision, Inc.11$73,7252023
AtriCure, Inc.2$71,0752023
Glaukos Corporation251$68,6002023
Mannkind Corporation4$65,8142023
Bayer Healthcare Pharmaceuticals Inc.2$64,3402023
Johnson & Johnson Vision Care, Inc.2$62,7482023
bioMerieux Inc2$61,9372023
TG Therapeutics, Inc.2$57,7302023
Alcon Research LLC25$57,5772023
Ipsen Bioscience Inc.6$57,0422023
GENZYME CORPORATION19$50,0732023
Alkermes, Inc.3$47,6172023
Daiichi Sankyo Inc.14$39,0262023
Sage Therapeutics, LLC1$38,4442023
Pharming Healthcare, Inc.1$38,0002023
UCB SA2$36,8512023
KLS-Martin L.P.7$34,2502023
Veru Inc.2$30,7002023
SpectraWAVE, Inc2$29,2002023
LivaNova USA, Inc.2$26,4802023
GlaxoSmithKline, LLC.1$25,4042023

By nature of payment

NatureRecordsAmount
Research payment1,544$9,383,243
Grant24$583,911
Space rental or facility fees (teaching hospital only)47$206,081
Charitable Contribution2$192,500
Consulting Fee18$156,049
Compensation for services other than consulting, including serving as faculty or as a speaker at a v34$30,035
Royalty or License3$22,507
Education1$20,000
Debt forgiveness2$14,095
Long term medical supply or device loan7$4,560

Records

DateCompanyAmountNatureFormProductStudyYear
2023-12-31Gilead Sciences, Inc.$398,566GrantCash or cash equivalent2023
2023-12-31Merck Sharp & Dohme LLC$198,327Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYPhase I,II study of laser interstitial thermotherapy LITT combined with checkpoint inhibitor for recurrent GBM2023
2023-12-31Merck Sharp & Dohme LLC$145,540Research paymentCash or cash equivalent Biological, CARDIOVASCULARA Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept versus Placebo for 2023
2023-12-31Merck Sharp & Dohme LLC$57,720Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy vers2023
2023-12-31Siemens Medical Solutions USA, Inc.$54,246Research paymentIn-kind items and servicesTrueBeam Device, OncologyA Prospective Imaging Study of Target Definition and Radiation Planning Workflows on the Integrated TrueBeam-HyperSight 2023
2023-12-31Mannkind Corporation$28,763Research paymentCash or cash equivalentAFREZZA Drug, DIABETES MEDICINEINHALE-12023
2023-12-31Siemens Medical Solutions USA, Inc.$25,800Research paymentIn-kind items and servicesEvaluation of AIRC Brain Morphometry2023
2023-12-31Merck Sharp & Dohme LLC$18,609Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in2023
2023-12-31Merck Sharp & Dohme LLC$18,252Research paymentIn-kind items and servicesLENVIMA Drug, ONCOLOGYA Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-792023
2023-12-31Merck Sharp & Dohme LLC$6,252Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 3, Randomized, Double-blind Study of Pembrolizumab MK-3475 Plus Docetaxel Plus Prednisone versus Placebo Plus Do2023
2023-12-31Medtronic, Inc.$4,371Research paymentIn-kind items and servicesCIP337 SUCCEED2023
2023-12-31Merck Sharp & Dohme LLC$3,791Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently2023
2023-12-31Merck Sharp & Dohme LLC$3,483Research paymentIn-kind items and services Biological, CARDIOVASCULARA Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept versus Placebo for 2023
2023-12-31Stryker Corporation$1,231Long term medical supply or device loanIn-kind items and servicesREMB Device, SURGICAL2023
2023-12-31ABBVIE INC.$1,220Research paymentIn-kind items and servicesStudy to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously2023
2023-12-31Merck Sharp & Dohme LLC$1,102Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Pembrolizumab in Combination with Cisplatin a2023
2023-12-31ABBVIE INC.$875Research paymentIn-kind items and servicesA Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Sma2023
2023-12-31Stryker Corporation$799Long term medical supply or device loanIn-kind items and servicesREMB Device, SURGICAL2023
2023-12-31Stryker Corporation$799Long term medical supply or device loanIn-kind items and servicesREMB Device, SURGICAL2023
2023-12-31Stryker Corporation$799Long term medical supply or device loanIn-kind items and servicesREMB Device, SURGICAL2023
2023-12-31Stryker Corporation$799Long term medical supply or device loanIn-kind items and servicesREMB Device, SURGICAL2023
2023-12-31Merck KGaA$689Research paymentCash or cash equivalentTEPMETKO Drug, OncologyA randomized, double-blind placebo-controlled, Phase 3 study of Debio 1143 in combination with platinum-based chemothera2023
2023-12-31ABBVIE INC.$687Research paymentIn-kind items and servicesLINZESS Drug, GASTROENTEROLOGYA Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Safety and Efficacy Study of Linaclotide Versus Placeb2023
2023-12-31Merck Sharp & Dohme LLC$435Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg2023
2023-12-31Merck Sharp & Dohme LLC$204Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-792023
2023-12-31Merck Sharp & Dohme LLC$158Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase II Clinical Trial of Single Agent Pembrolizumab MK-3475 in Subjects with Recurrent or Metastatic Head and Neck S2023
2023-12-31Merck Sharp & Dohme LLC$157Research paymentIn-kind items and servicesNOXAFIL Drug, INFECTIOUS DISEASEPhase IB study of the Safety, Tolerance, and Pharmacokinetics of Oral Posaconazole in Immunocompromised Children with Ne2023
2023-12-31ABBVIE INC.$94Research paymentIn-kind items and servicesA Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumor2023
2023-12-31ABBVIE INC.$88Research paymentIn-kind items and servicesBOTOX Biological, FACIAL AESTHETICSStudy of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Inte2023
2023-12-31Merck Sharp & Dohme LLC$78Research paymentIn-kind items and servicesNOXAFIL Drug, INFECTIOUS DISEASEA Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous IV and Powder for Oral Suspension Formulations2023
2023-12-31ABBVIE INC.$58Research paymentIn-kind items and servicesRINVOQ Biological, IMMUNOLOGYStudy to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatri2023
2023-12-31Merck Sharp & Dohme LLC$51Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized Open-Label Phase III Study of Single Agent Pembrolizumab versus Single Agent Chemotherapy per Physician s C2023
2023-12-31Fisher & Paykel Healthcare Inc$23Long term medical supply or device loanIn-kind items and servicesFISHER & PAYKEL HEALTHCARE Device, Heated respiratory humidifier2023
2023-12-31Merck Sharp & Dohme LLC$14Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 2, Randomized, Double-Blind Study of Pembrolizumab MK-3475 plus Epacadostat INCB024360 Versus Pembrolizumab plus2023
2023-12-31Merck Sharp & Dohme LLC$6Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase III Randomized Clinical Trial of Pembrolizumab MK-3475 versus Paclitaxel, Docetaxel or Vinflunine in Subjects wi2023
2023-12-31Merck Sharp & Dohme LLC$4Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA phase III study of Lenalidomide and low-dose Dexamethasone with or without Pembrolizumab MK3475 in newly diagnosed and2023
2023-12-31Merck Sharp & Dohme LLC$0Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase II Study of Pembrolizumab Monotherapy in Third-line Previously Treated Subjects with Advanced,Metastatic Adenoca2023
2023-12-29Cochlear Americas$812Research paymentCash or cash equivalentOSIA OSI300 IMPLANT Device, Implantable hearing solutionOsia 2 System in a pediatric expansion study2023
2023-12-29ARGENX US, INC.$40Research paymentIn-kind items and servicesVYVGART HYTRULO Drug, ImmunologyA Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and the Safety of 2023
2023-12-28ABBVIE INC.$12,860Research paymentCash or cash equivalentORILISSA Drug, WOMENS HEALTHA Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-A2023
2023-12-28Medtronic, Inc.$500Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsLow Risk Bicuspid2023
2023-12-28Medtronic, Inc.$500Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsLow Risk Bicuspid2023
2023-12-26ABBVIE INC.$250Research paymentCash or cash equivalentBOTOX Biological, FACIAL AESTHETICSStudy of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Inte2023
2023-12-25Johnson & Johnson Vision Care, Inc.$47,847Research paymentCash or cash equivalentVision Performance of a Soft Contact Lens with Myopia Control Optics in a Pediatric Population2023
2023-12-22AstraZeneca Pharmaceuticals LP$40,180Research paymentCash or cash equivalentA Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigato2023
2023-12-22Cochlear Americas$883Research paymentCash or cash equivalentCochlear Implant With Dexamethasone Eluting Electrode Array2023
2023-12-21ABBVIE INC.$3,050Research paymentCash or cash equivalentStudy to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously2023
2023-12-21ABBVIE INC.$2,866Research paymentCash or cash equivalentStudy to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously2023
2023-12-21ABBVIE INC.$1,708Research paymentCash or cash equivalentStudy to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously2023
2023-12-21ABBVIE INC.$1,373Research paymentCash or cash equivalentStudy to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously2023
2023-12-21ABBVIE INC.$1,373Research paymentCash or cash equivalentStudy to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously2023
2023-12-21ABBVIE INC.$1,373Research paymentCash or cash equivalentStudy to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously2023
2023-12-21ABBVIE INC.$1,170Research paymentCash or cash equivalentStudy to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously2023
2023-12-21ABBVIE INC.$1,170Research paymentCash or cash equivalentStudy to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously2023
2023-12-21ABBVIE INC.$617Research paymentCash or cash equivalentBOTOX Biological, FACIAL AESTHETICSStudy of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Inte2023
2023-12-21Medtronic, Inc.$538Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsSMART Trial2023
2023-12-21ABBVIE INC.$466Research paymentCash or cash equivalentStudy to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously2023
2023-12-21ABBVIE INC.$466Research paymentCash or cash equivalentStudy to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously2023
2023-12-21ABBVIE INC.$466Research paymentCash or cash equivalentStudy to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously2023
2023-12-21ABBVIE INC.$466Research paymentCash or cash equivalentStudy to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously2023
2023-12-21ABBVIE INC.$466Research paymentCash or cash equivalentStudy to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously2023
2023-12-21ABBVIE INC.$466Research paymentCash or cash equivalentStudy to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously2023
2023-12-21ABBVIE INC.$466Research paymentCash or cash equivalentStudy to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously2023
2023-12-21ABBVIE INC.$466Research paymentCash or cash equivalentStudy to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously2023
2023-12-21ABBVIE INC.$466Research paymentCash or cash equivalentStudy to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously2023
2023-12-21ABBVIE INC.$466Research paymentCash or cash equivalentStudy to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously2023
2023-12-21ABBVIE INC.$466Research paymentCash or cash equivalentStudy to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously2023
2023-12-21ABBVIE INC.$466Research paymentCash or cash equivalentStudy to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously2023
2023-12-21ABBVIE INC.$466Research paymentCash or cash equivalentStudy to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously2023
2023-12-21ABBVIE INC.$466Research paymentCash or cash equivalentStudy to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously2023
2023-12-21ABBVIE INC.$466Research paymentCash or cash equivalentStudy to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously2023
2023-12-21ABBVIE INC.$466Research paymentCash or cash equivalentStudy to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously2023
2023-12-21ABBVIE INC.$466Research paymentCash or cash equivalentStudy to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously2023
2023-12-21ABBVIE INC.$466Research paymentCash or cash equivalentStudy to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously2023
2023-12-21ABBVIE INC.$466Research paymentCash or cash equivalentStudy to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously2023
2023-12-21ABBVIE INC.$466Research paymentCash or cash equivalentStudy to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously2023
2023-12-21ABBVIE INC.$466Research paymentCash or cash equivalentStudy to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously2023
2023-12-21ABBVIE INC.$466Research paymentCash or cash equivalentStudy to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously2023
2023-12-21ABBVIE INC.$466Research paymentCash or cash equivalentStudy to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously2023
2023-12-21ABBVIE INC.$466Research paymentCash or cash equivalentStudy to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously2023
2023-12-21ABBVIE INC.$466Research paymentCash or cash equivalentStudy to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously2023
2023-12-21ABBVIE INC.$466Research paymentCash or cash equivalentStudy to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously2023
2023-12-21ABBVIE INC.$466Research paymentCash or cash equivalentStudy to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously2023
2023-12-21ABBVIE INC.$466Research paymentCash or cash equivalentStudy to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously2023
2023-12-21ABBVIE INC.$466Research paymentCash or cash equivalentStudy to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously2023
2023-12-21ABBVIE INC.$466Research paymentCash or cash equivalentStudy to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously2023
2023-12-21ABBVIE INC.$466Research paymentCash or cash equivalentStudy to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously2023
2023-12-21ABBVIE INC.$466Research paymentCash or cash equivalentStudy to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously2023
2023-12-21ABBVIE INC.$466Research paymentCash or cash equivalentStudy to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously2023
2023-12-21ABBVIE INC.$466Research paymentCash or cash equivalentStudy to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously2023
2023-12-21ABBVIE INC.$466Research paymentCash or cash equivalentStudy to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously2023
2023-12-21ABBVIE INC.$466Research paymentCash or cash equivalentStudy to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously2023
2023-12-21ABBVIE INC.$466Research paymentCash or cash equivalentStudy to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously2023
2023-12-21ABBVIE INC.$466Research paymentCash or cash equivalentStudy to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously2023
2023-12-21ABBVIE INC.$466Research paymentCash or cash equivalentStudy to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously2023
2023-12-21ABBVIE INC.$466Research paymentCash or cash equivalentStudy to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously2023
2023-12-21ABBVIE INC.$466Research paymentCash or cash equivalentStudy to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously2023
2023-12-21ABBVIE INC.$466Research paymentCash or cash equivalentStudy to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously2023
2023-12-21ABBVIE INC.$466Research paymentCash or cash equivalentStudy to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously2023
2023-12-20SEAGEN INC.$9,065Research paymentCash or cash equivalentA Phase 1 Study of SEA-CD70 in Myeloid Malignancies2023
2023-12-20SEAGEN INC.$4,565Research paymentCash or cash equivalentA Phase 1 Study of SEA-CD70 in Myeloid Malignancies2023
2023-12-20SEAGEN INC.$2,250Research paymentCash or cash equivalentTUKYSA Drug, OncologyA Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer 2023
2023-12-20ABBVIE INC.$1,250Research paymentCash or cash equivalentStudy to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administer2023
2023-12-20Glaukos Corporation$810Research paymentCash or cash equivalentiStent inject Trabecular Micro-Bypass System Model G2-M-IS Device, GlaucomaiStent Inject Trabecular Micro-Bypass System New Enrollment Post-Approval Study2023
2023-12-20Glaukos Corporation$630Research paymentCash or cash equivalentiStent inject Trabecular Micro-Bypass System Model G2-M-IS Device, GlaucomaiStent Inject Trabecular Micro-Bypass System New Enrollment Post-Approval Study2023
2023-12-20Abbott Laboratories$500Research paymentCash or cash equivalentCARDIOMEMS Device, Heart FailureHemodynamic-GUIDEd Management of Heart Failure2023
2023-12-20Glaukos Corporation$280Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentiDose TR Drug, Glaucoma2023
2023-12-20Glaukos Corporation$270Research paymentCash or cash equivalentiStent inject Trabecular Micro-Bypass System Model G2-M-IS Device, GlaucomaiStent Inject Trabecular Micro-Bypass System New Enrollment Post-Approval Study2023
2023-12-20Glaukos Corporation$230Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentiDose TR Drug, Glaucoma2023
2023-12-20SEAGEN INC.$200Research paymentCash or cash equivalentTUKYSA Drug, OncologyA Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer 2023
2023-12-20Glaukos Corporation$180Research paymentCash or cash equivalentiStent inject Trabecular Micro-Bypass System Model G2-M-IS Device, GlaucomaiStent Inject Trabecular Micro-Bypass System New Enrollment Post-Approval Study2023
2023-12-20Glaukos Corporation$180Research paymentCash or cash equivalentIDOSE TR Drug, GlaucomaProspective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophtha2023
2023-12-20Glaukos Corporation$180Research paymentCash or cash equivalentiStent inject Trabecular Micro-Bypass System Model G2-M-IS Device, GlaucomaiStent Inject Trabecular Micro-Bypass System New Enrollment Post-Approval Study2023
2023-12-20Glaukos Corporation$90Research paymentCash or cash equivalentiStent inject Trabecular Micro-Bypass System Model G2-M-IS Device, GlaucomaiStent Inject Trabecular Micro-Bypass System New Enrollment Post-Approval Study2023
2023-12-20Glaukos Corporation$90Research paymentCash or cash equivalentIDOSE TR Drug, GlaucomaProspective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophtha2023
2023-12-20Glaukos Corporation$90Research paymentCash or cash equivalentIDOSE TR Drug, GlaucomaProspective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophtha2023
2023-12-20Glaukos Corporation$90Research paymentCash or cash equivalentIDOSE TR Drug, GlaucomaProspective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophtha2023
2023-12-20Glaukos Corporation$90Research paymentCash or cash equivalentiStent inject Trabecular Micro-Bypass System Model G2-M-IS Device, GlaucomaiStent Inject Trabecular Micro-Bypass System New Enrollment Post-Approval Study2023
2023-12-20Glaukos Corporation$90Research paymentCash or cash equivalentIDOSE TR Drug, GlaucomaProspective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophtha2023
2023-12-20Glaukos Corporation$90Research paymentCash or cash equivalentiStent inject Trabecular Micro-Bypass System Model G2-M-IS Device, GlaucomaiStent Inject Trabecular Micro-Bypass System New Enrollment Post-Approval Study2023
2023-12-20Glaukos Corporation$90Research paymentCash or cash equivalentIDOSE TR Drug, GlaucomaProspective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophtha2023
2023-12-20Glaukos Corporation$90Research paymentCash or cash equivalentIDOSE TR Drug, GlaucomaProspective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophtha2023
2023-12-19ARGENX US, INC.$2,900Research paymentCash or cash equivalentVYVGART HYTRULO Drug, ImmunologyAn Open-Label, Multicenter, Follow-up Trial of ARGX-113-1904 to Evaluate the Safety, Tolerability, and Efficacy of Efgar2023
2023-12-19Travere Therapeutics, Inc.$2,047Research paymentCash or cash equivalent021IGAN170012023
2023-12-19ARGENX US, INC.$1,000Research paymentCash or cash equivalentVYVGART HYTRULO Drug, ImmunologyAn Open-Label, Multicenter, Follow-up Trial of ARGX-113-1904 to Evaluate the Safety, Tolerability, and Efficacy of Efgar2023
2023-12-19Saluda Medical Americas, Inc.$907Research paymentCash or cash equivalentEvoke SCS Device, Spinal Cord StimulationECAP Study2023
2023-12-19Regeneron Pharmaceuticals, Inc.$558Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFECT OF DUPILUMAB ON EXERCISE CAP2023
2023-12-19ARGENX US, INC.$500Research paymentCash or cash equivalentVYVGART HYTRULO Drug, ImmunologyAn Open-Label, Multicenter, Follow-up Trial of ARGX-113-1904 to Evaluate the Safety, Tolerability, and Efficacy of Efgar2023
2023-12-18Boston Scientific Corporation$11,095Research paymentCash or cash equivalentClinical Trial Product Device, Clinical Trial Product ICACURATE IDE2023
2023-12-18GENZYME CORPORATION$6,741Consulting FeeCash or cash equivalent2023
2023-12-18Boston Scientific Corporation$750Research paymentCash or cash equivalentClinical Trial Product Device, Clinical Trial Product ICCHAMPION AF2023
2023-12-15ABBVIE INC.$15,680Research paymentCash or cash equivalentStudy to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Ind2023
2023-12-15Baxter Healthcare$14,080Debt forgivenessIn-kind items and services Device, Trauma (Emergency, Injury, Surgery)2023
2023-12-15ABBVIE INC.$9,800Research paymentCash or cash equivalentStudy to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Ind2023
2023-12-15Abbott Laboratories$4,000Research paymentCash or cash equivalentXIENCE V Device, VascularOptical Coherence Tomography (OCT) Guided Coronary Stent Implantation Compared to Angiography: a Multicenter Randomized 2023
2023-12-15ABBVIE INC.$3,500Research paymentCash or cash equivalentStudy to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Ind2023
2023-12-15Janssen Research & Development, LLC$3,000Research paymentCash or cash equivalentA Randomized, Stratified, Double-blind, Placebo-Controlled Study to Investigate the Efficacy, Safety and Tolerability of2023
2023-12-15Janssen Research & Development, LLC$3,000Research paymentCash or cash equivalentA Randomized, Stratified, Double-blind, Placebo-Controlled Study to Investigate the Efficacy, Safety and Tolerability of2023
2023-12-15ABBVIE INC.$2,800Research paymentCash or cash equivalentStudy to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Ind2023
2023-12-15ABBVIE INC.$2,800Research paymentCash or cash equivalentStudy to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Ind2023
2023-12-15Abbott Laboratories$750Research paymentCash or cash equivalentESPRIT Device, VascularLIFE-BTK (Pivotal Investigation of Safety and Efficacy of BRS Treatment-Below The Knee) Randomized Controlled Trial2023
2023-12-14Siemens Medical Solutions USA, Inc.$10,404Space rental or facility fees (teaching hospital only)Cash or cash equivalent2023
2023-12-14ABBVIE INC.$3,213Research paymentCash or cash equivalentStudy to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously2023
2023-12-14ABBVIE INC.$2,572Research paymentCash or cash equivalentStudy to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously2023
2023-12-14ABBVIE INC.$2,177Research paymentCash or cash equivalentStudy to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously2023
2023-12-14ABBVIE INC.$1,708Research paymentCash or cash equivalentStudy to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously2023
2023-12-14ABBVIE INC.$1,170Research paymentCash or cash equivalentStudy to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously2023
2023-12-14ABBVIE INC.$900Research paymentCash or cash equivalentStudy to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously2023
2023-12-14ABBVIE INC.$900Research paymentCash or cash equivalentStudy to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously2023
2023-12-14Alcon Research LLC$660Research paymentCash or cash equivalentHYDRUS Microstent Device, OphthalmologyThe Hydrus Microstent New Enrollment Post-Approval Study: A Prospective, Non-Randomized, Multicenter, Single Arm Clinica2023
2023-12-14ABBVIE INC.$220Research paymentCash or cash equivalentORILISSA Drug, WOMENS HEALTHStudy Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea R2023
2023-12-13Roche Products Limited$15,686Research paymentCash or cash equivalentActemra Biological, ImmunologyMorpheus UC2023
2023-12-12Siemens Medical Solutions USA, Inc.$34,685Research paymentCash or cash equivalentTrueBeam Device, OncologyA Prospective Imaging Study of Target Definition and Radiation Planning Workflows on the Integrated TrueBeam-HyperSight 2023
2023-12-12Regeneron Healthcare Solutions, Inc.$1,000GrantCash or cash equivalentLIBTAYO Biological, ONCOLOGY2023
2023-12-12Cochlear Americas$65Research paymentCash or cash equivalentCOCHLEAR NUCLEUS CI632 COCHLEAR IMPLANT WITH SLIM MODIOLAR ELECTRODE Device, Implantable hearing solutionPerimodiolar Implant Performance in Adults with Low-Frequency Residual Hearing2023
2023-12-11ABBVIE INC.$3,050Research paymentCash or cash equivalentStudy to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously2023
2023-12-11ABBVIE INC.$3,013Research paymentCash or cash equivalentStudy to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously2023
2023-12-11ABBVIE INC.$3,013Research paymentCash or cash equivalentStudy to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously2023
2023-12-11Johnson & Johnson Surgical Vision, Inc.$2,890Research paymentCash or cash equivalentVSCO-110-LOKE_Cornea Image Analysis Reading Center2023
2023-12-11Johnson & Johnson Surgical Vision, Inc.$2,890Research paymentCash or cash equivalentVSCO-110-LOKE_Cornea Image Analysis Reading Center2023
2023-12-11ABBVIE INC.$2,275Research paymentCash or cash equivalentStudy to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously2023
2023-12-11ABBVIE INC.$1,708Research paymentCash or cash equivalentStudy to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously2023
2023-12-11ABBVIE INC.$1,373Research paymentCash or cash equivalentStudy to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously2023
2023-12-11ABBVIE INC.$1,373Research paymentCash or cash equivalentStudy to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously2023
2023-12-11Cochlear Americas$883Research paymentCash or cash equivalentCochlear Implant With Dexamethasone Eluting Electrode Array2023
2023-12-11GENZYME CORPORATION$238Research paymentCash or cash equivalentATLAS-PEDS: An Open-label, Multinational Study of Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12023
2023-12-08Stryker Corporation$33,150Research paymentCash or cash equivalentT2 Device, TRAUMA & EXTREMETIESA RETROSPECTIVE DATA COLLECTION OF THE TREATMENT OF FEMORAL FRACTURES WITH THE T2 ALPHA FEMUR RETROGRADE NAILING SYSTEM2023
2023-12-08Regeneron Pharmaceuticals, Inc.$3,500Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN PEDIATRIC PA2023
2023-12-08Regeneron Pharmaceuticals, Inc.$2,500Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN PEDIATRIC PA2023
2023-12-08Ipsen Pharma SAS$2,276Research paymentCash or cash equivalentA Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Saf2023
2023-12-08Takeda Pharmaceuticals U.S.A., Inc.$2,000Research paymentCash or cash equivalentA PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATR2023
2023-12-08Takeda Pharmaceuticals U.S.A., Inc.$1,500Research paymentCash or cash equivalentA PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATR2023
2023-12-08Takeda Pharmaceuticals U.S.A., Inc.$1,500Research paymentCash or cash equivalentA PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATR2023
2023-12-08Takeda Pharmaceuticals U.S.A., Inc.$1,250Research paymentCash or cash equivalentA PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATR2023
2023-12-08Cochlear Americas$1,141Research paymentCash or cash equivalentCOCHLEAR NUCLEUS CI632 COCHLEAR IMPLANT WITH SLIM MODIOLAR ELECTRODE Device, Implantable hearing solutionPerimodiolar Implant Performance in Adults with Low-Frequency Residual Hearing2023
2023-12-08Regeneron Pharmaceuticals, Inc.$1,000Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN PEDIATRIC PA2023
2023-12-08Takeda Pharmaceuticals U.S.A., Inc.$1,000Research paymentCash or cash equivalentA PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATR2023
2023-12-08Takeda Pharmaceuticals U.S.A., Inc.$975Research paymentCash or cash equivalentA PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATR2023
2023-12-08Cochlear Americas$883Research paymentCash or cash equivalentCochlear Implant With Dexamethasone Eluting Electrode Array2023
2023-12-08Takeda Pharmaceuticals U.S.A., Inc.$600Research paymentCash or cash equivalentA PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATR2023
2023-12-08Takeda Pharmaceuticals U.S.A., Inc.$500Research paymentCash or cash equivalentA PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATR2023
2023-12-07ABBVIE INC.$25,312Research paymentCash or cash equivalentA Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Sma2023
2023-12-07ABBVIE INC.$10,364Research paymentCash or cash equivalentVENCLEXTA Drug, ONCOLOGYA Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allog2023
2023-12-07Ethicon Inc.$7,565Research paymentCash or cash equivalentA Post Approval Study of the LINX Reflux Management System2023
2023-12-07Ethicon Inc.$3,210Research paymentCash or cash equivalentA Prospective Multi Center Study of Reflux Management with the LINX System for Gastroesophageal REFlux Disease after Lap2023
2023-12-07ABBVIE INC.$2,209Research paymentCash or cash equivalentA Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and or Refractory Solid Tumor2023
2023-12-07Genmab U.S., Inc.$874Research paymentCash or cash equivalentFirst-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With 2023
2023-12-07Medtronic, Inc.$350Research paymentCash or cash equivalentSYMPLICITY G3 Device, Renal Denervation SystemSPYRAL HTN-ON MED Expan2023
2023-12-06SEAGEN INC.$6,913Research paymentCash or cash equivalentTUKYSA Drug, OncologyA Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer 2023
2023-12-06SEAGEN INC.$5,000Research paymentCash or cash equivalentA Platform Study Master Protocol to Evaluate the Antitumor Activity and Safety of Targeted Therapeutic Agents in Subject2023
2023-12-06Centinel Spine, LLC$4,032Research paymentCash or cash equivalentPRODISC C SK Device, Spine ImplantA Multicenter, Prospective, Randomized, Controlled Trial Comparing the Safety and Effectiveness of Prodisc C SK and Prod2023
2023-12-06Bolton Medical Inc$3,360Research paymentCash or cash equivalentRELAY THORACIC STENT-GRAFT WITH PLUS DELIVERY SYSTEM Device, ENDOVASCULAR AORTIC REPAIRPANTHER2023
2023-12-06Abbott Laboratories$1,227Research paymentCash or cash equivalentMITRACLIP Device, VascularPercutaneous MitraClip Device or Surgical Mitral Valve Repair in Patients with PrImary Mitral Regurgitation Who Are Cand2023
2023-12-04Medtronic, Inc.$8,150Research paymentCash or cash equivalentCG FUTURE Device, Heart ValvesHVT PMCF Registry2023
2023-12-04ABBVIE INC.$3,945Research paymentCash or cash equivalentA Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants2023
2023-12-04ABBVIE INC.$3,013Research paymentCash or cash equivalentSKYRIZI Biological, IMMUNOLOGYStudy to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to 2023
2023-12-04ABBVIE INC.$790Research paymentCash or cash equivalentCREON Drug, ENDOCRINOLOGYStudy to Evaluate Symptoms of Exocrine Pancreatic Insufficiency in Adult Participants With Cystic Fibrosis or Chronic Pa2023
2023-12-04GENZYME CORPORATION$714Research paymentCash or cash equivalentATLAS-PEDS: An Open-label, Multinational Study of Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12023
2023-12-01SEAGEN INC.$44,079Research paymentCash or cash equivalentA Phase 2 Multi Cohort, Open Label, Multi-Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin 2023
2023-12-01ARGENX US, INC.$7,764Research paymentCash or cash equivalentVYVGART Drug, ImmunologyEfficacy and Safety Study of Efgartigimod in Adults With Post-COVID-19 POTS2023

The latest 200 records of 1,682.

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Cuyahoga CountyCleveland city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Cleveland, OH, county Cuyahoga County, OH, state Ohio; placed by its city name.

MeasurePlace (city or town)
Cleveland, OH
County
Cuyahoga County, OH
State
Ohio
Population B01003366,0971,245,87311,810,293
Population, 2020 census P1372,6241,264,81711,799,448
Median age B0100236.340.439.7
Under 18 B0100121.0%20.5%22.0%
65 and over B0100115.2%19.5%18.3%
Households B11001169,683554,5514,863,191
Foreign born B050026.3%7.7%5.2%
Median household income B19013$40,801$64,468$71,389
Median family income B19113$50,461$89,252$92,749
Per capita income B19301$28,266$42,747$40,552
Poverty rate B1700130.6%16.1%13.3%
Unemployment rate B2302510.8%6.6%4.8%
Civilian labor force B23025180,027650,5775,994,779
Mean commute (minutes) B0801322.523.323.4
Bachelor's degree or higher B1500322.4%36.5%31.5%
Housing units B25001201,141615,3315,292,391
Owner-occupied B2500341.7%59.4%67.2%
Renters B2500358.3%40.6%32.8%
Median home value B25077$102,000$195,400$214,800
Median gross rent B25064$945$1,060$1,034
White, not Hispanic B0300233.7%56.5%75.8%
Black B0300245.1%28.5%12.0%
Hispanic or Latino B0300213.2%7.0%4.8%
Asian B030022.6%3.3%2.5%
American Indian and Alaska Native B030020.1%0.1%0.1%

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Cleveland, OH.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.